ClinicalTrials.gg
CompletedNCT01189812Updated Aug 24, 2011Results posted

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

A Phase 2 interventional study of Lithium Carbonate and Placebo in Major Depressive Disorder, Dysthymia and Depression Not Otherwise Specified, sponsored by Columbia Northwest Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-08-24.

Sponsored by Columbia Northwest Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
605th of 1,323
80 · median 70
Started
2010
with 68 others
Phase 2
271 of 1,500
45 open now
Registered
393rd of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 605th largest by enrollment of the 1,323 interventional ones that give a count, is one of 69 that started in 2010, is one of 271 in phase 2, and was the 393rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.

03

Conditions studied

  • Major Depressive Disorder
  • Dysthymia
  • Depression Not Otherwise Specified
  • Borderline Personality Disorder

Keywords

  • hopelessness
  • alone
  • sad
  • troubled
  • depression
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-75 years of age
  • Meets criteria for Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified or Borderline Personality Disorder
  • Ability to speak, read and understand the English Language and provide written

Exclusion criteria

Exclusion Criteria:

  • Current, unstable and significant medical condition or illness
  • History of Thyroid disorder, seizure disorder, tumors or other CNS condition that predisposes the patient to risk of seizure
  • Pregnant or lactating females
  • Abnormal clinical laboratory test results
  • Intolerance or to SSRIs or lithium
  • History or current diagnosis of bipolar mood disorder, psychosis, schizophrenia or dementia
  • Certain mediations my not be used prior or during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Placebo comparator
    sugar pill

    Drug: Placebo · Drug: Citalopram

  • Active comparator
    Lithium

    Drug: Lithium Carbonate · Drug: Citalopram

Interventions

  • 300 mg one time per day for 4 weeks

  • DrugPlacebo

    Take one time daily for 4 weeks

  • All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)

    Also known as: Celexa

06

What researchers measure

Primary outcomes

  1. Sheehan-Suicidality Tracking Scale (S-STS)

    The S-STS is an 14 item clinician administered prospective rating scale that scores both treatment-emergent suicidal ideations and suicidal behaviors with scores ranging from 0-40 points. Patients scoring a 0 are experiencing no suicidal thoughts, ideations, or attempts, while a score of 40 indicates a fatal, completed suicide. Comparison was made between the citalopram with lithium and the citalopram with placebo treatment groups. Outcome measures are expressed as change scores from the baseline visit to week 4.

    Time frame: 4 weeks; from Baseline to Week 4

Secondary outcomes

  1. Beck Hopelessness Scale (BHS)

    The BHS measures the extent of negative attitudes about the future. It has particular utility as an indirect indicator of suicidal risk in depressed examinees or individuals who have made suicide attempts. Comparison between citalopram and lithium and citalopram and placebo groups in the BHS will be made from baseline to week 4

    Time frame: 4 weeks

  2. Beck Scale for Suicide Ideation (BSS)

    The BSS is a 21-item slef-report instrument used to detect ans measure the severity of suicidal ideation in adults. It measures a broad spectrum of attitudes and behaviors for assessing patient suicide risk, as well as reveals specific suicidal characteristics which require greater scrutiny. Comparison between citalopram and lithium and citalopram and placebo groups in the BSS will be made from baseline to week 4

    Time frame: 4 weeks

07

Results

Posted Jun 8, 2011

Participant flow

There were 93 patients screened to meet the enrollment target of 80 randomized subjects into this study. Subjects were recruited from two clinical research centers beginning in March 2010. One site was located in Bellevue, WA, and the other in San Diego, CA. The last patient was screened in December 2010.

Participant flow — Overall Study
MilestonePlacebo (Sugar Pill)Lithium
Started4040
Completed3232
Not completed88
Withdrew: Withdrawal by subject23
Withdrew: Adverse event10
Withdrew: Out of window43
Withdrew: Moved out of state12

Outcome measures

PrimarySheehan-Suicidality Tracking Scale (S-STS)

The S-STS is an 14 item clinician administered prospective rating scale that scores both treatment-emergent suicidal ideations and suicidal behaviors with scores ranging from 0-40 points. Patients scoring a 0 are experiencing no suicidal thoughts, ideations, or attempts, while a score of 40 indicates a fatal, completed suicide. Comparison was made between the citalopram with lithium and the citalopram with placebo treatment groups. Outcome measures are expressed as change scores from the baseline visit to week 4.

Time frame:
4 weeks; from Baseline to Week 4
Reported as:
Mean · Scores on a Scale (S-STSS)
Sheehan-Suicidality Tracking Scale (S-STS)
Scores on a Scale (S-STSS)Placebo (Sugar Pill)Lithium
Sheehan-Suicidality Tracking Scale (S-STS)4.8 ± 5.55.0 ± 5.1
SecondaryBeck Hopelessness Scale (BHS)

The BHS measures the extent of negative attitudes about the future. It has particular utility as an indirect indicator of suicidal risk in depressed examinees or individuals who have made suicide attempts. Comparison between citalopram and lithium and citalopram and placebo groups in the BHS will be made from baseline to week 4

Time frame:
4 weeks

Results for this outcome have not been posted.

SecondaryBeck Scale for Suicide Ideation (BSS)

The BSS is a 21-item slef-report instrument used to detect ans measure the severity of suicidal ideation in adults. It measures a broad spectrum of attitudes and behaviors for assessing patient suicide risk, as well as reveals specific suicidal characteristics which require greater scrutiny. Comparison between citalopram and lithium and citalopram and placebo groups in the BSS will be made from baseline to week 4

Time frame:
4 weeks
Reported as:
Mean · Participants

Results for this outcome have not been posted.

Adverse events

Collected over Adverse event reporting began at the time the patient screened for the study and signed the informed consent document. AEs were collected at each study visit and follow up phone call and could be reported 30 days after last dose of study medication.. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Sugar Pill)—1/40 (2.5%)18/40 (45%)
Lithium—1/40 (2.5%)21/40 (52.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Sugar Pill)Lithium
DepressionPsychiatric disorders1/400/40
PsoriasisSkin and subcutaneous tissue disorders0/401/40
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo (Sugar Pill)Lithium
HeadachesNervous system disorders1/409/40
SomnolenceNervous system disorders7/406/40
NauseaGastrointestinal disorders5/404/40
AnxiousnessPsychiatric disorders2/403/40
DyspepsiaGastrointestinal disorders0/403/40
Upper Respitory InfectionRespiratory, thoracic and mediastinal disorders3/400/40
DizzinessNervous system disorders2/402/40
VomitingGastrointestinal disorders1/402/40
Decreased AppetiteNervous system disorders2/402/40
RestlessnessNervous system disorders2/400/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo (Sugar Pill)LithiumTotal
<=18 years000
Between 18 and 65 years393978
>=65 years112
Age Continuous
Age Continuous(years)Placebo (Sugar Pill)LithiumTotal
Mean38.5 ± 15.245.0 ± 11.641.8 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Sugar Pill)LithiumTotal
Female251944
Male152136
Region of Enrollment
Region of Enrollment(participants)Placebo (Sugar Pill)LithiumTotal
United States404080
08

Study locations

2 sites
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2010
First posted
Aug 27, 2010
Start
Mar 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
Jun 8, 2011
Last update
Aug 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01189812
Lead sponsor
Columbia Northwest Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 27, 2010
Start date
Mar 2010
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Jun 8, 2011
Last update
Aug 24, 2011

Study contacts

Arifulla Khan, MD
principal investigator · Northwest Clinical Research Center
Vishaal Mehra, MD
principal investigator · Aretmis Institute for Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lithium Carbonate

Start the discussion